The remarkable aspect of the alleviation of anemia following the administration of an SGLT2 inhibitor lies in its long-lasting effects and its apparent independence from preexisting anemia or even from an existing iron deficiency status. This evidence concerns the gene SLC5A2 and Iron deficiency anemia.